VTGN - VistaGen Therapeutics, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
VistaGen Therapeutics, Inc.
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
IPO Date: July 1, 2011
Sector: Healthcare
Industry: Biotech
Market Cap: $10.97M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.10 | 5.44%
Avg Daily Range (30 D): $0.01 | 4.94%
Avg Daily Range (90 D): $0.03 | 6.77%
Institutional Daily Volume
Avg Daily Volume: 1.75M
Avg Daily Volume (30 D): 20.39M
Avg Daily Volume (90 D): 9.41M
Trade Size
Avg Trade Size (Sh.): 492
Avg Trade Size (Sh.) (30 D): 839
Avg Trade Size (Sh.) (90 D): 753
Institutional Trades
Total Institutional Trades: 84
Avg Institutional Trade: $2.29M
Avg Institutional Trade (30 D): $.59M
Avg Institutional Trade (90 D): $.59M
Avg Institutional Trade Volume: .22M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.82M
Avg Closing Trade (30 D): $.76M
Avg Closing Trade (90 D): $.76M
Avg Closing Volume: 147.97K
 
News
Jun 1, 2026 @ 6:40 PM
Kuehn Law Encourages Investors of Vistagen Therape...
Source: Kuehn Law, Pllc
Mar 14, 2026 @ 10:01 PM
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL,...
Source: Rosen Law Firm
Mar 12, 2026 @ 4:00 PM
Bronstein, Gewirtz & Grossman LLC Urges Vistagen T...
Source: Bronstein, Gewirtz & Grossman Llc
Mar 9, 2026 @ 2:00 PM
VTGN Investors Have Opportunity to Lead Vistagen T...
Source: The Schall Law Firm
Mar 7, 2026 @ 2:14 PM
VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM...
Source: Rosen Law Firm
Financials
  TTM Q1 2027 Q4 2026
Basic EPS $-1.66 $-.3 $-.37
Diluted EPS $-1.66 $-.3 $-.37
Revenue $2.5M $1.48M $.47M
Gross Profit
Net Income / Loss $-67.62M $-13.03M $-16.27M
Operating Income / Loss $-69.66M $-13.35M $-16.72M
Cost of Revenue
Net Cash Flow $-18.2M $M $-16.58M
PE Ratio    
Splits
Jun 07, 2023 1:30
Aug 14, 2014 1:20
Jun 10, 2011 2:1